# Safety, and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell)

> **NCT05084989** · PHASE2 · COMPLETED · sponsor: **Jiangsu Rec-Biotechnology Co., Ltd.** · enrollment: 948 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** Part1:Recombinant two-component COVID-19 vaccine (CHO cell)
- **BIOLOGICAL:** Part1: Placebo
- **BIOLOGICAL:** Part2: Recombinant two-component COVID-19 vaccine (CHO cell)
- **BIOLOGICAL:** Part2: COVID-19 Vaccine, mRNA

## Key facts

- **NCT ID:** NCT05084989
- **Lead sponsor:** Jiangsu Rec-Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-31
- **Primary completion:** 2022-08-18
- **Final completion:** 2023-02-09
- **Target enrollment:** 948 (ACTUAL)
- **Last updated:** 2024-02-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05084989

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05084989, "Safety, and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05084989. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*